Table 2.
Demographic and clinical characteristics of participating subjects (n = 275).
| Variable | Type of patient | Value of p | ||
|---|---|---|---|---|
| Total | Co-infected HIV/HBV | HIV positive | ||
| n = 275 (100%) | n = 32 (11.6%) | n = 243 (88.4%) | ||
| Gender | ||||
| Male | 179 (65.1%) | 21 (65.6%) | 158 (65%) | 1.0a |
| Age (median years-IQR) | ||||
| 38 (30–44) | 37 (31–42) | 38 (29–44) | 0.73b | |
| Risk factor | ||||
| Heterosexual | 182 (66.2%) | 22 (68.8%) | 160 (65.8%) | 0.52a |
| Homosexual | 24 (15.6%) | 8 (25%) | 35 (14.4%) | |
| Bisexual | 8 (5.8%) | 2 (6.2%) | 14 (5.8%) | |
| ND | 31 (12.4%) | 0 (0%) | 34 (14.0%) | |
| CDC HIV classification | ||||
| A | 83 (30.2%) | 10 (31.3%) | 73 (30.0%) | 0.62a |
| B | 95 (34.5%) | 13 (40.6%) | 82 (33.7%) | |
| C | 89 (32.4%) | 9 (28.1%) | 80 (32.9%) | |
| ND | 8 (2.9%) | 0 (0%) | 8 (3.3%) | |
| CD4+ count (cells/mm3) | ||||
| Median - IQR | 342 (200–532) | 316 (183–447) | 347 (203–532) | |
| <200 | 68 (24.7%) | 9 (28.1%) | 59 (24.3%) | 0.70a |
| 200–500 | 128 (46.6%) | 16 (50%) | 112 (46.1%) | |
| >500 | 79 (28.7%) | 7 (21.9%) | 72 (29.6%) | |
| HIV viral load (copies/mL) | ||||
| Median-IQR | 84 (40–8,615) | 702.5 (40–32188.8) | 80 (40–7220.5) | |
| Undetectable ≤50 | 119 (43.2%) | 12 (37.5%) | 107 (44.0%) | 0.20a |
| Low 51–10,000 | 94 (34.2%) | 9 (28.1%) | 85 (35.0%) | |
| Mid 10,001-99,999 | 42 (15.3%) | 9 (28.1%) | 33 (13.6%) | |
| High >100,000 | 20 (7.3%) | 2 (6.3%) | 18 (7.4%) | |
| HBV serologic markers | ||||
| HBsAg | ||||
| Negative | 266 (96.7%) | 23 (71.9%) | 243 (100%) | <0.05a,* |
| Positive | 9 (3.3%) | 9 (28.1%) | 0 (0%) | |
| Anti-HBc | ||||
| Negative | 206 (74.9%) | 19 (59.4%) | 187 (77%) | 0.05a,* |
| Positive | 69 (25.1%) | 13 (40.6%) | 56 (23%) | |
| Anti-HBs | ||||
| Negative | 168 (61.1%) | 22 (68.7%) | 146 (60.1%) | 0.45a |
| Positive | 107 (38.9%) | 10 (31.3%) | 97 (39.9%) | |
| HBV vaccination | ||||
| No | 54 (19.6%) | 8 (25%) | 46 (18.9%) | 0.29a |
| Yes | 47 (17.1%) | 3 (9.4%) | 44 (18.1%) | |
| ND | 174 (63.3%) | 21 (65.6%) | 153 (63.0%) | |
ND, No data; HBsAg, hepatitis B surface antigen; Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody; CDC, Center for Disease Control and Prevention; IQR, interquartile range. aChi square test; bMann–Whitney test. *Statistical differences were observed.